Northwire Canada EditionThursday, August 6, 2026
Sign inSubscribe
Northwire
⌕
ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2% ARTG 37.67 +7.3% SAGE 0.120 +4.3% NTR 93.88 −0.3% ERO 42.71 +4.6% EDR 12.55 +7.1% IFOS 2.23 −0.5% URE 1.80 −2.2% AAUC 27.50 +4.3% IMR 0.145 +3.6% EQX 14.50 +7.4% OGC 37.67 +6.8% TFPM 43.89 +4.4% SGD 15.42 +5.4% BKM 2.55 +3.2% OR 45.20 +4.4% CDE 24.46 +7.2%

← Back to our analysis

Original News Release

Optimind cancels Monjin acquisition

Optimind Pharma Corp Sep 05, 2025 · 04:30 OMND As distributed — unedited
Mr. Rakesh Malhotra reports OPTIMIND PHARMA ANNOUNCES TERMINATION OF LETTER OF INTENT Optimind Pharma Corp.'s previously announced non-binding letter of intent dated March 18, 2025, with Monjin Interviews Pvt. Ltd., with respect to the company's acquisition of Monjin, has been mutually terminated by the parties. The company is continuing to evaluate and review alternative acquisition opportunities. About Optimind Pharma Corp. The company is a reporting issuer in Canada and is listed on the Canadian Securities Exchange under the symbol OMND. We seek Safe Harbor.
View at source ↗